SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

AI-powered diagnostics, smart lenses, and connected wearables are redefining global eye health by enabling early detection, ...

ST. LOUIS, MO - January 23, 2026 - PRESSADVANTAGE - Brinton Vision today announced the release of its new article, ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

SightMD is proud to welcome two outstanding eye care professionals, William Boozan, MD and Tracey Rosenlicht, OD, to its growing network of providers. Their combined expertise enhances SightMD's ...

Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...

Patient awareness of glaucoma differs markedly depending on urban and rural locations and the patient population, and that awareness or lack thereof impacts diagnosis, treatment, ...

January 15, 2026 - PRESSADVANTAGE - Lucent Vision has published a new educational resource titled “What Practice Offers ...

When our practice adopted the Light Adjustable Lens in 2022, we did so with a clear purpose of helping patients with corneal ...

Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of “The Savvy Senior” book.

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...